Dave Eyerman

DDF Discovery

Dave brings over 15 years of Neuroscience research to the Dementia Discovery Fund U.S. Discovery team

In December 2018, Dave joined the Dementia Discovery Fund U.S. Discovery (“DUS”) team as Head of Biology of the Daionus project, which aims to develop effective treatments for Alzheimer’s disease and other dementias by rescuing disease-associated endo-lysosomal trafficking defects.

Prior experience
From June 2017 to December 2018, Dave was Director of In-Vivo Pharmacology at Fulcrum Therapeutics in Cambridge, MA.  In this role, he built internal and external in-vivo pharmacology capabilities, developed overarching strategy and led in-vivo activities, including PK, PK/PD, target engagement, efficacy and early safety studies, to support non-clinical development of prospective small molecule therapies for rare, monogenic diseases.  From July 2008 to June 2018, Dave worked in varying roles, lastly as the Head of CNS Disease Biology, at Alkermes Inc.  There he led and managed research teams tasked with identifying and developing novel small molecule therapeutics for the treatment of neuropsychiatric disorders, drug abuse and pain.  Prior to joining industry, Dave was a Research Fellow at Mclean Hospital and the Department of Psychiatry at Harvard Medical School.

Academic credentials
B.A. in Biological Psychology from Skidmore College
Ph.D. in Pharmacology and Experimental Therapeutics from Boston University School of Medicine
Postdoctoral Research at Harvard Medical School and Mclean Hospital

Outside of SV
Dave enjoys big mountain skiing, soccer and time with his family

Dementia Discovery Fund